Validating the regulatory expectations on evidential requirements for predictive biomarkers is not a trivial process, but quite conceptually challenging.
Innovation was the watchword at CAR-TCR in Boston last month, but one of the limitations of innovation is that it can be challenging for an industry to transition from the rapid iteration s
In the Middle East and North Africa, cancer is growing at an alarming rate, and – as Economist Impact notes – the region is on the cusp of a demographic transition, with UNICEF predicting t
